What Валз Н treats: Main Uses and Benefits

Валз Н is a combination medication commonly used in the management of high blood pressure, known as essential hypertension, in adults. The fundamental purpose is to achieve sustained and stable control of elevated systemic pressure, which may assist with maintaining functional stability of the circulatory system. This combination is commonly used to help treat high blood pressure, as lowering it may assist with reducing the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions.

The primary indications for Валз Н include addressing persistently elevated blood pressure that remains uncontrolled by single-agent therapy, managing pressure associated with Stage 2 hypertension, and may be relevant for initial combination therapy in situations where dual action is appropriate. This focus may help patients cope more steadily with symptom fluctuations related to pressure control.

Support for Uncontrolled and High-Risk Hypertension

Валз Н is applied strategically when patients exhibit an inadequate response to single-agent therapy, meaning one drug alone may not be enough to meet blood pressure targets. This makes it relevant for add-on therapy or may be considered for initial therapy for individuals with high blood pressure. The medication generally provides the necessary dual support and may assist with easing the overall symptomatic burden and supports general pressure stability.

---

Quick Fact: Relief for Chronic Strain
Primary Indication	Essential Hypertension (Mild to Moderate)
Use Context	When monotherapy fails or dual action is required
Therapeutic Benefit	Supports reduction of major cardiovascular risks

---

Long-Term Cardiovascular and Organ Protection

By effectively normalizing blood pressure, Валз Н supports the mitigation of chronic strain placed upon the circulatory system, including the heart and kidneys. This long-term support generally contributes to easing the overall symptom load associated with major cardiovascular risk, and supports general well-being during symptomatic phases.

Regulatory References

1. NIH MedlinePlus overview

Eligibility Map: Who Can and Cannot Use Валз Н

This section details the official population eligibility and non-eligibility rules for Валз Н (Valsartan/Hydrochlorothiazide), based strictly on governmental regulatory documents.

---

Eligibility Scope

Category	Official Regulatory Status
Populations Allowed	Adults with Essential Hypertension.
Contraindicated Populations	Pregnant women (discontinue immediately upon detection); Patients with Anuria; Patients with Severe Renal Impairment (GFR <30 mL/min); Patients with Severe Hepatic Impairment (including cholestasis).
Hypersensitivity	Contraindicated for those allergic to any component or to sulfonamide-derived drugs.
Pediatric Use	Not recommended for children and adolescents under 18 years due to safety and efficacy not being established.
Comorbidity Restriction	Contraindicated for patients with diabetes mellitus taking aliskiren.
Lactation	Not recommended; nursing or the drug should be discontinued.

---

Eligibility-Related Restrictions

Use requires caution in patients with mild to moderate hepatic impairment or unilateral/bilateral renal artery stenosis. The medicine is also contraindicated in patients with certain refractory electrolyte imbalances (like hypokalemia or hypercalcemia).

Interactions with other medicines and products

Official regulatory information classifies specific drug combinations and substance categories that may interact with Валз Н (Valsartan/Hydrochlorothiazide).

Formal Restrictions and Contraindicated Use

Co-administration with Aliskiren is strictly documented as a contraindicated combination in patients diagnosed with diabetes or those who have moderate to severe renal impairment. Regulatory labeling also highlights that the co-use of Lithium can lead to an increased risk of Lithium toxicity due to the reduced renal clearance caused by the hydrochlorothiazide component.

---

Pharmacodynamic and Exposure-Altering Interactions

• Potassium-Sparing Agents and Supplements: Co-administration with potassium-sparing diuretics, potassium supplements, or salt substitutes containing potassium is noted for an elevated risk of hyperkalemia (excessive potassium in the blood) due to additive pharmacodynamic effects.
• NSAIDs: Non-Steroidal Anti-Inflammatory Drugs, including COX-2 inhibitors, may reduce the intended antihypertensive and diuretic effects of Валз Н. This interaction may also heighten the risk of acute renal impairment, a risk specified as greater in patients with existing renal compromise.
• Transporter Inhibitors: The Valsartan component is a substrate for the OATP1B1 and MRP2 hepatic transporters. Co-administered inhibitors of these transporters, such as Rifampin, Cyclosporine, and Ritonavir, may increase the systemic exposure (plasma concentrations) of Valsartan.
• Cholestyramine and Colestipol: These agents are documented to interfere with the gastrointestinal absorption of the hydrochlorothiazide component, generally necessitating a time separation requirement for administration.
• Alcohol and Narcotics: Co-administration may potentiate the risk of orthostatic hypotension.

Валз Н is a fixed-dose combination composed of valsartan, an angiotensin II receptor blocker (ARB), and hydrochlorothiazide (HCTZ), a thiazide diuretic, each component modulating distinct physiological pathways to affect system-level fluid and vascular dynamics.

Valsartan acts as a selective antagonist at the Angiotensin II Type 1 ( AT1) receptor, primarily located on vascular smooth muscle and adrenal glands. By binding to and blocking the AT1 receptor, valsartan prevents the agonistic action of the peptide Angiotensin II. This blockade inhibits the downstream cellular processes that typically lead to arteriolar vasoconstriction and the stimulation of aldosterone release, resulting in a reduction of peripheral vascular resistance.

Hydrochlorothiazide operates in the kidney by selectively inhibiting the sodium-chloride cotransporter (NCC) located on the apical membrane of the distal convoluted tubule. This inhibition decreases the tubular reabsorption of sodium and chloride ions, thereby increasing the excretion of these electrolytes and accompanying water into the urine. This process, known as natriuresis and diuresis, decreases extracellular fluid volume and plasma volume, contributing to reduced overall vascular volume.

Валз Н is a fixed-dose combination product administered orally once daily. The film-coated tablet may be taken with or without food and should be swallowed whole with water.

Standard Dosage and Frequency

Usage Parameter	Official Adult Instructions (V/HCTZ)
Route of Administration	Oral Tablet
Usual Starting Dose	160 mg/12.5 mg once daily
Maximum Daily Dose	320 mg/25 mg once daily
Dose Titration	May be considered after 1 to 2 weeks of therapy

The maximum antihypertensive effects following a dose change are generally attained within two to four weeks.

Population-Specific Use and Administration Rules

For older adults (elderly patients), no initial dosage adjustment is required. The use of Valsartan/Hydrochlorothiazide is not recommended in the pediatric population (patients under 18 years of age) as safety and efficacy have not been established in this group.

Regarding renal function, no initial dose adjustment is required for patients with mild to moderate renal impairment (creatinine clearance 30 mL/min). However, the medicine is not recommended for patients with severe renal impairment (creatinine clearance < 30 mL/min) due to the Hydrochlorothiazide component. Additionally, any existing intravascular volume depletion must be corrected before treatment is initiated. If a dose is missed, the patient should skip the missed dose and resume the regular schedule if it is almost time for the next dose; double doses are prohibited.

Research evidence / Overview of Studies for Валз Н

Evidence for Use in Essential Hypertension

The core research for Валз Н (Valsartan/Hydrochlorothiazide) was studied for its evaluation in the context of essential hypertension (high blood pressure) in adults. The evidence primarily comes from short-term, randomized controlled trials (RCTs). This design was applied in studies examining how blood pressure measurements change over defined time intervals. Research reports average Systolic (SBP) and Diastolic Blood Pressure (DBP) measurements in groups receiving the combination therapy, groups receiving placebo, and groups receiving either drug component alone. Studies monitored the percentage of patients who achieved specific, predefined blood pressure goals during the observation period.

---

How the Combination Was Studied Against Monotherapy

Studies primarily examined the observed blood pressure patterns of the fixed-dose combination compared to its single components. These comparative studies focused on patients with uncontrolled hypertension. Research explored short-term changes by measuring blood pressure over periods often lasting 8 to 12 weeks. Research has observed the patterns of blood pressure targets reached among patients receiving the combination compared to those receiving monotherapy. This evidence contributes to understanding the patterns observed in blood pressure measurements.

---

Long-Term Studies and Cardiovascular Outcomes

The overall long-term aim of addressing high blood pressure is to explore patterns related to major cardiovascular events, such as stroke and myocardial infarction (heart attack). The long-term evidence related to fatal and nonfatal cardiovascular events is primarily derived from large-scale, controlled trials of the individual drug classes (Angiotensin II Receptor Blockers and Diuretics) over periods of several years. The research regarding long-term cardiovascular events is considered an extrapolated finding, derived from the patterns of blood pressure changes observed in those broader, longer-duration drug class studies.

---

What Remains Uncertain About the Research Landscape

While the research provides clear context on the patterns observed with the combination on short-term blood pressure measurements, the primary limitation is that the follow-up durations for the head-to-head combination studies were often limited (e.g., to a few months). Consequently, long-term effects on sustained blood pressure measurements and patient-reported outcomes over multiple years are not fully established by these specific trials. Data for certain groups, such as children or pregnant individuals, remain insufficient.

Common questions about Валз Н (FAQ)

Q: What is Valz H and what is it used for?

A: Valz H is a combination medication that contains valsartan and hydrochlorothiazide. It is used to treat high blood pressure (hypertension).

• Valsartan is an angiotensin II receptor blocker (ARB). It works by blocking a substance in the body called angiotensin II, which causes blood vessels to tighten. By blocking this, valsartan helps to relax the blood vessels and lower blood pressure.
• Hydrochlorothiazide is a thiazide diuretic, or "water pill." It helps the body get rid of excess water and salt through increased urine flow, which also helps to lower blood pressure.

Lowering high blood pressure helps to reduce the risk of serious problems like stroke, heart attack, and kidney failure.

---

Q: How should I take Valz H?

A: You should take Valz H exactly as your doctor prescribes. The tablets are usually taken once a day with or without food. You should try to take your dose at about the same time each day.

Do not stop taking this medication without consulting your doctor, even if your blood pressure seems controlled, as your blood pressure could increase again.

---

Q: What should I do if I miss a dose of Valz H?

A: If you miss a dose, take it as soon as you remember. However, if it is almost time for your next scheduled dose, skip the missed dose and continue with your regular dosing schedule. Do not take a double dose to make up for the one you missed.

---

Q: What are the possible side effects of Valz H?

A: Valz H can cause side effects. Some common side effects may include:

• Dizziness or lightheadedness
• Headache
• Tiredness or fatigue
• Nausea or stomach pain
• Cough

Hydrochlorothiazide, the diuretic component, can also cause changes in the body's electrolyte (such as potassium and sodium) and blood sugar levels. Your doctor may check your blood periodically to monitor for these changes.

Contact your doctor immediately if you experience signs of a serious reaction, such as swelling of the face, lips, tongue, or throat (angioedema), or symptoms of an electrolyte imbalance like muscle weakness, confusion, or an irregular heartbeat.

---

Q: Can I take Valz H if I am pregnant?

A: No, Valz H (valsartan and hydrochlorothiazide) is not recommended during pregnancy and must not be taken if you are more than three months pregnant, as it can cause serious harm or even death to the developing fetus.

If you become pregnant while taking Valz H, you should stop taking it and contact your doctor immediately to discuss alternative treatments. If you are planning to become pregnant, you should also discuss this with your doctor.

Storage and Disposal Conditions for Valsartan and Hydrochlorothiazide

The official label requires Valsartan and Hydrochlorothiazide tablets (Валз Н) to be stored at Controlled Room Temperature, specifically between 68 F and 77 F (20 C to 25 C). The medication must be protected from excess heat and moisture and kept from freezing to maintain stability. Tablets should remain in a tightly closed container.

Handling and Protection

The product must be stored out of the reach and sight of children to prevent accidental ingestion. Do not keep medicine that is expired or no longer needed. Disposal of unused or expired tablets must follow the specific instructions provided by a healthcare professional or pharmacist to ensure proper handling.